Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day: Polyclonal plasma cell (PolyPC) signature may be a key indicator for predicting progression of MGUS to myeloma; sensitivity and specificity were 70% (28/40) and 81.7% (273/334).”
Title: Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma
Authors: Fumou Sun, Yan Cheng, Catherine Ma, Hongwei Xu, Clyde Bailey, David Mery, Timothy Cody Ashby, Daisy Alapat, Yong Li, Ken H Young, Samer Al Hadidi, Sharmilan Thanendrarajan, Carolina Schinke, Maurizio Zangari, Frits van Rhee, Guido Tricot, John D Shaughnessy, Jr, Fenghuang Zhan.
You can read the Full Article in Cancer Biomarkers.
More posts featuring Robert Orlowski.
